Daily Updates
ASCO Is Open. The Plenary Is Tomorrow. Here’s What Else Happened.
ASCO 2026 opened today at McCormick Place in Chicago. More than 40,000 attendees. More than 7,000 abstracts. The energy across the conference is focused squarely
Your fast, high-signal look at everything that moved biotech, medtech, and pharma today. The BioMed Nexus Daily Update delivers the most important regulatory moves, trial readouts, deals, and industry developments in one concise, easy-to-scan report. Updated every weekday morning.
ASCO 2026 opened today at McCormick Place in Chicago. More than 40,000 attendees. More than 7,000 abstracts. The energy across the conference is focused squarely
ASCO abstracts are out, and the early standout is a dataset that could reshape the largest oncology franchise in the world. Merck and Kelun-Biotech’s sacituzumab
Ten deals. Twenty-five billion dollars. Five months. Eli Lilly announced agreements on May 26 to acquire three privately held vaccine developers in simultaneous transactions totaling
Three days. That is the distance between now and the opening of the most important oncology meeting of the year. Revolution Medicines’ plenary session on
This is ASCO week. The most anticipated oncology event of the year opens Thursday in Chicago and runs through June 2. Revolution Medicines’ plenary session
Retatrutide is the most effective weight-loss drug ever tested in a Phase 3 trial. Eli Lilly reported positive topline results from the TRIUMPH-1 trial on
The FDA is now operating with acting leaders in every senior position that matters for drug and biologics review. Within days of Commissioner Makary’s May
Merck’s sac-TMT Phase 3 win is the most important ADC data point since Enhertu’s early breast cancer approval last week. Sacituzumab tirumotecan, an antibody-drug conjugate
The World Health Organization declared the Ebola outbreak in the Democratic Republic of the Congo and Uganda a Public Health Emergency of International Concern on
Three stories from the weekend reshape their respective markets. The Supreme Court ruled to maintain mifepristone access while litigation continues, resolving the near-term regulatory uncertainty